With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

The possible usefulness of alpha-synuclein (aSyn) determinations in peripheral tissues
(blood cells, salivary gland biopsies, olfactory mucosa, digestive tract, skin) and in biological …

Background and Objectives Multiple system atrophy (MSA) is a progressive
neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the …

There is an urgent need to find reliable and accessible blood-based biomarkers for early
diagnosis of Parkinson's disease (PD) correlating with clinical symptoms and displaying …

Clinical differentiation of progressive supranuclear palsy (PSP) from Parkinson's disease
(PD) is challenging due to overlapping phenotypes and the late onset of specific atypical …

Lewy body diseases (LBD) are pathologically defined as the accumulation of Lewy bodies
composed of an aggregation of α-synuclein (αSyn). In LBD, not only the sole aggregation of …

Biomarkers in Parkinson's disease are widely researched in the field of neuropsychiatry.
Though Parkinson's disease is diagnosed clinically, biomarkers prove to be a promising …

Abstract N6‐methyladenosine (m6A), an emerging modification of messenger RNA, has
been implicated in many biological processes. However, its role in Parkinson's disease (PD) …

Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of
disease-modifying treatments for Parkinson's disease (PD) but there is no current consensus …

Background Parkinson's disease (PD) is an increasingly common neurodegenerative
condition, which causes movement dysfunction and a broad range of non-motor symptoms …